Design and results of phase I cancer clinical trials: Three-year experience at M.D. Anderson Cancer Center

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 287-295

  Smith, T L ^a   Lee, J J ^a   Kantarjian, H M ^a   Legha, S S ^a   Raber, M N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 8ALPHA (CARBAMOYLOXYMETHYL) 3,9 EPOXY 5 FORMYL 1,1A,2,8,9,9A OCTAHYDROAZIRINO[2,3 C][1]BENZAZOCINE 7,9 DIOL ACETATE; AMONAFIDE; CISPLATIN; DIDEMNIN B; DOCETAXEL; ELSAMICIN A; ETOPOSIDE; FAZARABINE; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 3; MITOXANTRONE; PLATINUM; RETINOIC ACID; TOPOTECAN; TRIMETREXATE; TUMOR NECROSIS FACTOR;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MONITORING; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030044379     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.287     Document Type: Article

References (46)

1. Geller NL: Design of phase I and II clinical trials in cancer: A statistician's view. Cancer Invest 2:483-491, 1984
2. Edler L: Statistical requirements of phase I studies. Onkologie 13:90-95, 1990
3. Ratain MJ, Mick R, Schilsky RL, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643, 1993
4. Hawkins MJ: Early cancer clinical trials: Safety, numbers, and consent. J Natl Cancer Inst 85:1618-1619, 1993
5. Korn EL, Midthune D, Chen TT, et al: A comparison of two phase I trial designs. Stat Med 13:1799-1806, 1994
6. Christian MC, Korn EL: The limited precision of phase I trials. J Natl Cancer Inst 86:1662-1663, 1994
7. Schneiderman MA: Statistical problems in bringing a drug clinical trial, in Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, vol 4. Berkeley, CA, University of California, 1967, pp 855-866
8. Freireich EJ, Gehan EA, Rall DP: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219-244, 1966
9. Penta JS, Rozencweig M, Guarino AM: Mouse and large-animal toxicology studies of twelve antitumor agents: Relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol 3:97-101, 1979
10. Storer B: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
11. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
12. Gatsonis C, Greenhouse JB: Bayesian methods for phase I clinical trials. Stat Med 11:1377-1389, 1992
13. Mick R, Lane N, Daugherty C, et al: Physician-determined patient risk of toxic effects: Impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst 86:1685-1693, 1994
14. O'Quigley J: Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 48:853-862, 1992
15. Chevret S: The continual reassessment method in cancer phase I clinical trials: A simulation study. Stat Med 12:1093-1108, 1993
16. Goodman SN, Zahurak M, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Stat Med 13:1-13, 1994
17. Collins JM, Grieshaber CK, Chabner BA: Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82:1321-1326, 1990
18. Mick R, Ratain MJ: Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision. J Natl Cancer Inst 85:217-223, 1993
19. Protocol Data Management System. Houston, TX, The University Texas M.D. Anderson Cancer Center, 1993
20. BMDP Statistical Software Manual. Berkeley, CA, University of California, 1992
21. Dhingra K, Talpaz M, Dhingra HM, et al: A phase I trial of recombinant alpha-2a (Roferon-A) with weekly cisplatinum. Invest New Drugs 9:37-39, 1991
22. Shin DM, Holoye PY, Murphy WK, et al: Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: Neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol 29:145-149, 1991
23. Raber MN, Newman RA, Newman BM, et al: Phase I trial and clinical pharmacology of elsamitrucin. Cancer Res 52:1406-1410, 1992
24. Fraschini G, Holmes F, Esparza L, et al: Phase I-II study of high-dose etoposide in patients with refractory breast cancer. Invest New Drugs 9:365-367, 1991
25. Amato R, Ho D, Schmidt S, et al: Phase I trial of a 72-h continuous-infusion schedule of fazarabine. Cancer Chemother Pharmacol 30:321-324, 1992
26. Pazdur R, Dah HH, Daugherty K, et al: Phase I trial of FK973: Description of a delayed vascular leak syndrome. Invest New Drugs 9:377-382, 1991
27. Moore DF, Pazdur R: Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 15:464-466, 1992
28. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
29. Jones D, Patt YZ, Ajani JA, et al: A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer 72:2560-2563, 1993
30. 1) platinum in patients with metastatic solid tumors. Cancer Chemother Pharmacol 31:333-337, 1993
31. Lee JS, Newman RA, Lippman SM, et al: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966, 1993
32. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84:1781-1788, 1992
33. Huan SD, Legha SS, Raber MN, et al: Phase I studies of Irimetrexate using single and weekly dose schedules. Invest New Drugs 9:199-206, 1991
34. O'Brien S, Benvenuto JA, Estey E, et al: Phase I clinical investigation of benzisoquinoloinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 51:935-938, 1991
35. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: A phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
36. Kantarjian H, Beran M, Ellis A, et al: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993
37. Danhauser LL, Freimann JHJ, Gilchrist TL, et al: Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol 11:751-761, 1993
38. Yang SC, Grimm EA, Parkinson DR, et al: Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor a in patients with advanced non-small cell lung cancer: A phase I trial. Cancer Res 51:3669-3676, 1991
39. Ziegler LD, Palazzolo P, Cunningham J, et al: Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 10:1470-1478, 1992
40. Dhingra K, Duvic M, Hymes S, et al: A phase-I clinical study of low-dose oral interferon-α. J Immunother 14:51-55, 1993
41. Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241-1250, 1991
42. Wittes RE: Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1989
43. Bodey GP, Legha S: The phase I study: General objectives, methods and evaluation, in Muggia FM, Rozencweig M (eds): Clinical Evaluation of Antitumor Therapy. Dordrecht, the Netherlands, Nijhoff, 1987, pp 153-174
44. Estey E, Hoth D, Simon R, et al: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105-1115, 1986
45. Penta JS, Rosner GL, Trump DL: Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol 31:247-250, 1992
46. Von Hoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115-122, 1991